BCG-unresponsive non-muscle invasive bladder cancer: recommendations from the IBCG

被引：103

作者：

Kamat, Ashish M. ^{[1
]}

Colombel, Marc ^{[2
]}

Sundi, Debasish ^{[1
]}

Lamm, Donald ^{[3
,4
]}

Boehle, Andreas ^{[5
]}

Brausi, Maurizio ^{[6
]}

Buckley, Roger ^{[7
]}

Persad, Raj ^{[8
,9
]}

Palou, Joan ^{[10
]}

Soloway, Mark ^{[11
]}

Witjes, J. Alfred ^{[12
]}

机构：

[1] MD Anderson Canc Ctr, Dept Urol, 1515 Holcombe Blvd,Unit 1373, Houston, TX 77054 USA

[2] Univ Claude Bernard, Hop Edouard Herriot, Dept Urol, Urol Pavillon 5,5 Pl Arsonval, F-69003 Lyon, France

[3] Univ Arizona, Dept Surg, 3815 East Bell Rd,Suite 1210, Phoenix, AZ 85032 USA

[4] BCG Oncol, 3815 East Bell Rd,Suite 1210, Phoenix, AZ 85032 USA

[5] HELIOS Agnes Karll Hosp, Dept Urol, Hochkamp 21, D-23611 Bad Schwartau, Germany

[6] B Ramazzini Hosp, AUSL Modena, Dept Urol, Via G Molinari 1, I-41012 Carpi Modena, Italy

[7] North York Gen Hosp, Dept Urol, 1333 Sheppard Ave East,Suite 222, N York, ON M2J 1V1, Canada

[8] Southmead Hosp, Dept Urol Surg, Brunel Bldg,Southmead Rd, Bristol BS10 5NB, Avon, England

[9] Bristol Urol Inst, Brunel Bldg,Southmead Rd, Bristol BS10 5NB, Avon, England

[10] Univ Autonoma Barcelona, Fundacio Puigvert, Dept Urol, Carrer Cartagena 340-350, Barcelona 08025, Spain

[11] Mem Hlth Syst, Mem Canc Inst, Div Urol Oncol, 20801 Biscayne Blvd,Suite 203, Aventura, FL 33180 USA

[12] Radboud Univ Nijmegen, Med Ctr, Dept Urol, POB 9101, NL-6500 HGB Nijmegen, Netherlands

来源：

NATURE REVIEWS UROLOGY | 2017年 / 14卷 / 04期

关键词：

BACILLUS-CALMETTE-GUERIN; CARCINOMA IN-SITU; TRANSITIONAL-CELL CARCINOMA; PHASE-II TRIAL; RANDOMIZED CONTROLLED-TRIAL; SOUTHWEST-ONCOLOGY-GROUP; SINGLE-CENTER EXPERIENCE; MITOMYCIN-C; UROTHELIAL CARCINOMA; ELECTROMOTIVE MITOMYCIN;

D O I：

10.1038/nrurol.2017.16

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Intravesical immunotherapy with live attenuated BCG remains the standard of care for patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Most patients initially respond, but recurrence is frequent and progression to invasive cancer is a concern. No established and effective intravesical therapies are available for patients whose tumours recur after BCG, representing a clinically important unmet need. Development and discovery of treatment options for BCG-unresponsive NMIBC is a high priority in order to decrease the morbidity, burden of health-care expenditures, and mortality related to bladder cancer. This Review of treatment options after BCG failure focuses on principles of optimal management emerging therapies, thus enabling a synthesis of recommendations for management for such patients.

引用

页码：244 / 255

页数：12

共 50 条

[11] LATE CELL CYCLE SIGNATURES STRATIFY GEMDOCE RESPONSES FOR BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
Gabrielson, Andrew
Epstein, Gabriel
Feng, Mingxiao
Patel, Sunil
Kates, Max
Choi, Woonyoung
[J]. JOURNAL OF UROLOGY, 2023, 209 : E188 - E189
[12] Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer
Pijpers, Olga M.
Hendricksen, Kees
Mostafid, Hugh
de Jong, Florus C.
Rosier, Marloes
Mayor, Nikhil
de Jong, Joep J.
Boormans, Joost L.
[J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (02) : 62.e13 - 62.e20
[13] Re: Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials
不详
[J]. JOURNAL OF UROLOGY, 2021, 206 (04): : 1061 - 1062
[14] Phase II trial of intravesical camrelizumab in BCG-unresponsive high-risk non-muscle invasive bladder cancer
Shen, Yijun
Peng, Liangju
Xu, Peihang
Wang, Yanhao
Wang, Xiang
Yao Xudong
Liu, Yushan
Ye, Ding-Wei
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[15] PHASE 3 STUDY OF VICINEUM IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER: 24-MONTH RESULTS
O'Donnell, Michael
Shore, Neal
Keane, Thomas
Jewett, Michael
Dickstein, Rian
Wolk, Fred
Dillon, Rachelle L.
Cizeau, Jeannick
Kassouf, Wassim
[J]. JOURNAL OF UROLOGY, 2021, 206 : E296 - E297
[16] Race, ethnicity, and gender reporting in North American clinical trials for BCG-unresponsive non-muscle invasive bladder cancer
Fletcher, Sean A.
Bivalacqua, Trinity J.
Brawley, Otis W.
Kates, Max
[J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (05) : 195.e13 - 195.e18
[17] BCG unresponsive non-muscle invasive bladder cancer: The beginning of a new era?
Guerrero-Ramos, F.
[J]. ACTAS UROLOGICAS ESPANOLAS, 2023, 47 (06): : 329 - 331
[18] Required efficacy for novel therapies in BCG-unresponsive non-muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?
Wettstein, Marian S.
Naimark, David
Hermanns, Thomas
Herrera-Caceres, Jaime O.
Ahmad, Ardalan
Jewett, Michael A. S.
Kulkarni, Girish S.
[J]. CANCER MEDICINE, 2020, 9 (10): : 3287 - 3296
[19] Hyperthermic intravesical chemotherapy for BCG unresponsive or BCG ineligible non-muscle invasive bladder cancer
de Jong, Joep J.
Rosier, Marloes
Boormans, Joost L.
[J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (10) : 613 - 613
[20] ELICITATION OF HEALTH STATE UTILITIES ASSOCIATED PROGRESSION FROM BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) HEALTH STATES
Cooper, O.
Rentz, A.
Piglowska, N.
Smith, C.
Jakobsen, J.
Catto, J.
Niegisch, G.
Ghatnekar, O.
Swinburn, P.
[J]. VALUE IN HEALTH, 2022, 25 (07) : S288 - S288

← 1 2 3 4 5 →